These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10501488)

  • 21. Combined effect of C-reactive protein and stavudine on adipogenesis.
    Stankov MV; Schmidt RE; Behrens GM
    Antivir Ther; 2009; 14(6):819-29. PubMed ID: 19812444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of prior exposure to zidovudine on stavudine phosphorylation in vivo and ex vivo.
    Hoggard PG; Sales SD; Phiboonbanakit D; Lloyd J; Maher BA; Khoo SH; Wilkins E; Carey P; Hart CA; Back DJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):577-82. PubMed ID: 11158757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; McKinney RE; Nichols S; Mitchell WG; Yogev R; Hutcheon N
    Pediatrics; 1998 Feb; 101(2):214-20. PubMed ID: 9445494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemoenzymatic syntheses of homo- and heterodimers of AZT and d4T, and evaluation of their anti-HIV activity.
    Taourirte M; Mohamed LA; Rochdi A; Vasseur JJ; Fernández S; Ferrero M; Gotor V; Pannecouque C; De Clercq E; Lazrek HB
    Nucleosides Nucleotides Nucleic Acids; 2004; 23(4):701-14. PubMed ID: 15200032
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence and incidence of resistance to zidovudine and other antiretroviral drugs.
    Mayers DL
    Am J Med; 1997 May; 102(5B):70-5. PubMed ID: 9845501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis.
    Ahluwalia GS; Gao WY; Mitsuya H; Johns DG
    Mol Pharmacol; 1996 Jul; 50(1):160-5. PubMed ID: 8700108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of Human Endogenous Retrovirus Type K to Reverse Transcriptase Inhibitors.
    Contreras-Galindo R; Dube D; Fujinaga K; Kaplan MH; Markovitz DM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential susceptibility of retroviruses to nucleoside analogues.
    Rosenblum LL; Patton G; Grigg AR; Frater AJ; Cain D; Erlwein O; Hill CL; Clarke JR; McClure MO
    Antivir Chem Chemother; 2001 Mar; 12(2):91-7. PubMed ID: 11527046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancing effects of a mono-bromo substitution at the para position of the phenyl moiety on the metabolism and anti-HIV activity of d4T-phenyl methoxyalaninyl phosphate derivatives.
    Venkatachalam TK; Tai HL; Vig R; Chen CL; Jan ST; Uckun FM
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3121-6. PubMed ID: 9873688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line.
    Turriziani O; Simeoni E; Dianzani F; Antonelli G
    Antivir Ther; 1998; 3(3):191-4. PubMed ID: 10682138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selection of a T-cell line resistant to stavudine and zidovudine by prolonged treatment with stavudine.
    Turriziani O; Scagnolari C; Bambacioni F; Bellomi F; Focher F; Gentile M; Antonelli G
    Antivir Ther; 2002 Jun; 7(2):105-11. PubMed ID: 12212922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An HIV-1 215V mutant shows increased phenotypic resistance to d4T.
    Pernas M; López-Galíndez C
    Virus Res; 2008 Aug; 135(2):340-4. PubMed ID: 18482778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.
    Hoggard PG; Sales SD; Kewn S; Sunderland D; Khoo SH; Hart CA; Back DJ
    Antivir Chem Chemother; 2000 Nov; 11(6):353-8. PubMed ID: 11227992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New lipophilic derivatives of AZT and d4T 5'-phosphonates.
    Shirokova EA; Jasko MV; Khandazhinskaya AL; Yanvarev DV; Skoblov YS; Pronayeva TR; Fedyuk NV; Pokrovsky AG; Kukhanova MK
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):981-5. PubMed ID: 14565326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prodrugs of 2',3'-didehydro-3'-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation.
    Tortolani DR; Russell JW; Whiterock VJ; Hitchcock MJ; Ghazzouli I; Martin JC; Mansuri MM; Starrett JE
    J Pharm Sci; 1994 Mar; 83(3):339-43. PubMed ID: 8207678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant levels of intracellular stavudine triphosphate are found in HIV-infected zidovudine-treated patients.
    Becher F; Pruvost AG; Schlemmer DD; Créminon CA; Goujard CM; Delfraissy JF; Benech HC; Grassi JJ
    AIDS; 2003 Mar; 17(4):555-61. PubMed ID: 12598776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.
    Uckun FM; Qazi S; Venkatachalam TK
    Arzneimittelforschung; 2005; 55(4):223-31. PubMed ID: 15901046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients.
    Trabattoni D; Lo Caputo S; Biasin M; Seminari E; Di Pietro M; Ravasi G; Mazzotta F; Maserati R; Clerici M
    Clin Diagn Lab Immunol; 2002 Sep; 9(5):1114-8. PubMed ID: 12204968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.